1. Home
  2. MNY vs GANX Comparison

MNY vs GANX Comparison

Compare MNY & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNY
  • GANX
  • Stock Information
  • Founded
  • MNY 2014
  • GANX 2017
  • Country
  • MNY Singapore
  • GANX United States
  • Employees
  • MNY N/A
  • GANX N/A
  • Industry
  • MNY
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MNY
  • GANX Health Care
  • Exchange
  • MNY Nasdaq
  • GANX Nasdaq
  • Market Cap
  • MNY 45.1M
  • GANX 41.9M
  • IPO Year
  • MNY N/A
  • GANX 2021
  • Fundamental
  • Price
  • MNY $1.11
  • GANX $2.28
  • Analyst Decision
  • MNY
  • GANX Strong Buy
  • Analyst Count
  • MNY 0
  • GANX 5
  • Target Price
  • MNY N/A
  • GANX $7.60
  • AVG Volume (30 Days)
  • MNY 72.6K
  • GANX 264.8K
  • Earning Date
  • MNY 12-10-2024
  • GANX 11-14-2024
  • Dividend Yield
  • MNY N/A
  • GANX N/A
  • EPS Growth
  • MNY N/A
  • GANX N/A
  • EPS
  • MNY N/A
  • GANX N/A
  • Revenue
  • MNY $90,185,081.00
  • GANX N/A
  • Revenue This Year
  • MNY $18.50
  • GANX N/A
  • Revenue Next Year
  • MNY $24.83
  • GANX N/A
  • P/E Ratio
  • MNY N/A
  • GANX N/A
  • Revenue Growth
  • MNY 24.60
  • GANX N/A
  • 52 Week Low
  • MNY $0.85
  • GANX $0.89
  • 52 Week High
  • MNY $3.46
  • GANX $5.33
  • Technical
  • Relative Strength Index (RSI)
  • MNY 49.05
  • GANX 57.43
  • Support Level
  • MNY $1.07
  • GANX $2.06
  • Resistance Level
  • MNY $1.13
  • GANX $2.65
  • Average True Range (ATR)
  • MNY 0.05
  • GANX 0.29
  • MACD
  • MNY 0.00
  • GANX 0.01
  • Stochastic Oscillator
  • MNY 36.05
  • GANX 66.36

About MNY MoneyHero Limited

MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: